Han Mu

Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study

Jinliang Zhang, Xihao Zhang, Han Mu et al. · Frontiers in Oncology · 2021 · 74 citations · Full text

Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study

Weihao Zhang, Kai Zhang, Changfu Liu et al. · Frontiers in Immunology · 2023 · 45 citations · Full text

Neutrophil–lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib

Kai Wei, Meng Wang, Wei Zhang et al. · Medical Oncology · 2014 · 30 citations

Cancer Immunosurveillance, Hepatology, Medicine +9

Novel virtual hepatectomy is useful for evaluation of the portal territory for anatomical sectionectomy, segmentectomy, and hemihepatectomy

Shun‐ichi Ariizumi, Yutaka Takahashi, Yoshihito Kotera et al. · Journal of Hepato-Biliary-Pancreatic Sciences · 2012 · 19 citations

Hepatic artery infusion chemotherapy (HAIC) combined with sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC): A prospective, single-arm phase II trial.

Dongming Liu, Han Mu, Changfu Liu et al. · Journal of Clinical Oncology · 2022 · 17 citations

Surgical Oncology, Bevacizumab Biosimilar, Pathology +18